Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Centessa Pharmaceuticals (CNTA) Receivables - Other (2024 - 2026)

Centessa Pharmaceuticals has reported Receivables - Other over the past 2 years, most recently at $3.4 million for Q4 2025.

  • Quarterly Receivables - Other rose 1070.73% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 million through Dec 2025, up 1070.73% year-over-year, with the annual reading at $3.4 million for FY2025, 1070.73% up from the prior year.
  • Receivables - Other was $3.4 million for Q4 2025 at Centessa Pharmaceuticals, up from $1.9 million in the prior quarter.
  • Over five years, Receivables - Other peaked at $3.4 million in Q4 2025 and troughed at $287000.0 in Q4 2024.